Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in imatinib-resistant or intolerant Ph+ CML and Ph+ ALL
CTR20132958Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bosutinib in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Pfizer. Started Apr 2015; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20132958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132958.